Officials behind dengvaxia mess face raps -- Roque

OFFICIALS who would be found liable for the Dengvaxia mess could face charges, presidential spokesperson Harry Roque said yesterday.

“The (Department of Health) and the Senate are continuing with their investigation. Maybe cases would be filed against those who would be found to have committed mistakes,” presidential spokesperson Harry Roque told Palace reporters yesterday.

Roque said that President Duterte was also very clear when he said that there should be no finger-pointing in the aftermath of the scandal

“What was important was to ensure the health of our youth,” Roque  said.

Roque said the DoH had also been ordered to tightly monitor those who had received Dengvaxia shots.

Also yesterday, the Public Attorney’s Office (PAO) bared it would file criminal and administrative charges against those who approved the use of a dengue vaccine, after it found at least 7 children who died after receiving the drug.
The seven fatalities were all found to have had bleeding in their brains, hearts and lungs before they died, “within 10 or 11 days after Dengvaxia vaccination,” Public Attorney’s Office forensics laboratory director Erwin Erfe told a radio interview.
“May separate na criminal acts at may administrative case,” Chief Public Attorney  Persida  Rueda Acosta said.
Doctors involved could have their licenses revoked by the Professional Regulation Commission, it was learned.
Acosta however did not name those who will be included in the charges.
The government suspended its dengue vaccination program, but the drug was already administered to about 800,000 public school children.
The Department of Health procured P3 billion worth of Dengvaxia despite criticism that the drug was not tested thoroughly.
Last December, the Gabriela Women’s Party asked the Supreme Court to compel the DoH, the Department of Education, and the Department of Interior and Local Government to provide long-term consultations and treatment for more than 800,000 children who received the vaccine.